Notification for the Submission of Safety and Efficacy of FDC permitted to manufacture but not approved by DCGI
According to DCG (I) file No. 4-01/2013-DC (Misc 13-PSC) dated 15 Jan 2013, In respect of FDC Falling under definition of “New Drug” licensed by state licensing Authorities before 1.10.12, without the permission of DCG (I), it has been decided that the DCG (I) will ask all the state drug controllers to ask the concerned manufacturers to prove the Safety and Efficacy of such FDCs before CDSCO within a period of 18 months, failing which such FDCs will be considered for being prohibited for manufacture and marketing in the country.
The new FDCs, if any, licensed by the state licensing authorities after 01.10.12 without approval of DCG(I), the same will be considered for being prohibited for manufacture and marketing in the country.
Recent Posts
The Cosmeceuticals Grey Zone: When a Cosmetic Claim Risks Becoming a Drug Claim
“Cosmeceutical” is a popular marketing word. It suggests something more powerful than an ordinary Cosmetic — a product that treats skin condition, not just improves appearance. The problem is th..
Ingredient Safety Dossiers: Building a Defensible Package for Novel Actives
Companies developing Cosmetics with new or unusual active ingredients face a higher regulatory bar in India than those using well-established formulations. Understanding what “new” means under the..
Cosmetic Claims Substantiation: What Counts as Evidence Under Indian Rules
Walk down any Cosmetics aisle and you will see claims like “clinically proven,” “dermatologist tested,” or “reduces fine lines in two weeks.” These claims sell products — but under the C..
Need Help?
Submit your EnquiryOffice Locations
- Delhi
- Bangalore
- USA
- Singapore